Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Obesity Pill Race Heats Up as Novo, Roche and Terns Share Data
The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, but the comparisons are rife with confounding variables, leaving analysts unsure about where to place their bets.
13% weight loss in 3 months! Obesity pill amycretin shows promise of replacing Ozempic injections
A new drug called amycretin is stepping into the spotlight, boasting impressive results that have both researchers and those struggling with obesity sitting up and taking notice.
Novo Nordisk experimental obesity pill has mild-to-moderate side effects in trial
Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects.
Novo’s Obesity Pill Yields ‘Remarkable’ 13% Weight Loss, Investigators Say
On the heels of Terns’ positive Phase I results that analysts compared with Lilly’s and Pfizer’s weight loss pills in development, Novo Nordisk showcased more details about its own oral candidate.
Roche Shares Drop on Concern About Obesity Pill Side Effects
Roche Holding AG’s shares slid the most in more than a month after its closely-watched experimental obesity pill was tied to side effects, raising questions about the drugmaker’s competitiveness in the hottest new pharmaceutical market.
Novo Nordisk shares drop more than 4% on disappointing obesity pill data
Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from a Phase 2a trial of its experimental obesity pill monlunabant that came in below market expectations.
Novo Nordisk’s new weight-loss pill Amycretin beats Wegovy in early trial
Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster weight loss than Wegovy in early clinical trials, according to data presented Wednesday at the European Association for the Study of Diabetes.
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
Key Takeaways Novo Nordisk's U.S.-listed shares lost ground Friday after a Phase 2a trial of the pharmaceutical firm’s latest obesity treatment showed less effectiveness in higher doses.Based on the results,
Novo Nordisk stock tumbled over the latest results for its experimental weight loss pill
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.
Zacks.com on MSN
12d
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
Novo Nordisk’s NVO oral obesity pill, amycretin, showed faster weight loss than its blockbuster weekly injection, Wegovy (semaglutide), in a phase I study. Not only did NVO’s stock rise 4% in response ...
13d
on MSN
Roche Says Obesity Pill’s Side Effects Blunted by Gradual Dosing
Roche Holding AG said side effects in a highly anticipated study of its experimental obesity pill were milder when it eased ...
12d
on MSN
‘Dual-action’ weight-loss pill helps people drop 13% of body weight in three months in early trials
An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...
STAT
4d
Novo’s new obesity drug shows modest results, raises concerns of psychiatric side effects
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
4d
on MSN
Novo Shares Fall on Safety Data for New Weight-Loss Drug
Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback